Longevity swaps 'a natural hedge' for pharmaceutical and care home industries, says Swiss Re

daniel-ryan

As longevity risk attracts increasing attention among pension funds, market participants are questioning reinsurers’ capacity to cope with the growing demand, and are looking for alternative solutions. Pharmaceutical and care homes could provide the answer, according Swiss Re.

Daniel Ryan, head of life and health research at Swiss Re, suggests the nature of both industries means they could benefit from increasing longevity, making them ideal counterparties for longevity swap deals. “There are

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact info@risk.net or view our subscription options here: http://subscriptions.risk.net/subscribe

You are currently unable to copy this content. Please contact info@risk.net to find out more.

Sorry, our subscription options are not loading right now

Please try again later. Get in touch with our customer services team if this issue persists.

New to Risk.net? View our subscription options

Register

Want to know what’s included in our free membership? Click here

This address will be used to create your account

The future of life insurance

As the world constantly evolves and changes, so too does the life insurance industry, which is preparing for a multitude of challenges, particularly in three areas: interest rates, regulatory mandates and technology (software, underwriting tools and…

You need to sign in to use this feature. If you don’t have a Risk.net account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here